Early response to benralizumab in Canadian patients with severe eosinophilic asthma: Interim results from a prospective observational cohort

References

• Côté A, Godbout K, Boulet L-P. The management of severe asthma in 2020. Biochem Pharmacol. 2020;179:114112. doi:10.1016/j.bcp.2020.114112.
   PubMed Web of Science ®Google Scholar
• To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12(1):204. doi:10.1186/1471-2458-12-204.
   PubMed Web of Science ®Google Scholar
• Aleman F, Lim HF, Nair P. Eosinophilic endotype of asthma. Immunol Allergy Clin North Am. 2016;36(3):559−568. doi:10.1016/j.iac.2016.03.006.
   PubMed Web of Science ®Google Scholar
• Nelson RK, Bush A, Stokes J, Nair P, Akuthota P. Eosinophilic asthma. J Allergy Clin Immunol Pract. 2020;8(2):465–473. doi:10.1016/j.jaip.2019.11.024.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi: 10.1016/S0140-6736(16)31324-1.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi: 10.1016/S0140-6736(16)31322-8.
   PubMed Web of Science ®Google Scholar
• Lee JK, Amin S, Erdmann M, et al. Real-world observational study on the characteristics and treatment patterns of allergic asthma patients receiving omalizumab in Canada. Patient Prefer Adherence. 2020;14:725–735. doi:10.2147/PPA.S248324.
   PubMed Web of Science ®Google Scholar
• Lee JK, Gendron A, Knutson M, Sriskandarajah N, Mbuagbaw L, Noorduyn SG. Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study. ERJ Open Res. 2021;7(1):00778-2020. doi:10.1183/23120541.00778-2020.
   PubMedGoogle Scholar
• Pilette C, Canonica GW, Chaudhuri R, et al. REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. J Allergy Clin Immunol Pract. 2022;10(10):2646–2656. doi:10.1016/j.jaip.2022.05.042.
   PubMed Web of Science ®Google Scholar
• Harrison T, Canonica GW, Chupp G, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020;56(4):2000151. doi:10.1183/13993003.00151-2020.
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Burhan H, Menzies-Gow A, et al. Benralizumab effectiveness in severe asthma is independent of previous biologic use. J Allergy Clin Immunol Pract. 2022;10(6):1534–1544.e4. doi:10.1016/j.jaip.2022.02.014.
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496–506. doi:10.1016/j.chest.2020.08.2083.
   PubMed Web of Science ®Google Scholar
• Menzella F, Bargagli E, Aliani M, et al. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study. Respir Res. 2022;23(1):36. doi:10.1186/s12931-022-01952-8.
   PubMed Web of Science ®Google Scholar
• Padilla-Galo A, Levy-Abitbol R, Olveira C, et al. Real-life experience with benralizumab during 6 months. BMC Pulm Med. 2020;20(1):184. doi:10.1186/s12890-020-01220-9.
   PubMed Web of Science ®Google Scholar
• Roche N, Anzueto A, Bosnic Anticevich S, et al. The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group: Endorsed by the International Primary Care Respiratory Group and the World Allergy Organization. Eur Respir J. 2019;54(3):1901511. doi:10.1183/13993003.01511-2019.
   PubMed Web of Science ®Google Scholar
• Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907. doi:10.1034/j.1399-3003.1999.14d29.x.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Bousquet J, Abetz L, Bateman E, GOAL Committee. Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. Respir Med. 2006;100(4):616–621. doi:10.1016/j.rmed.2005.08.012.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened version of the asthma control questionnaire. Respir Med. 2005;99(5):553–558. doi:10.1016/j.rmed.2004.10.008.
   PubMed Web of Science ®Google Scholar
• Guertin JR, Feeny D, Tarride J. Age- and sex-specific Canadian utility norms, based on the 2013-2014 Canadian Community Health Survey. CMAJ. 2018;190(6):E155–E161. doi:10.1503/cmaj.170317.
   PubMed Web of Science ®Google Scholar
• Soong W, Chipps BE, O’Quinn S, et al. Health-realted quality of life and productivity among US patients with severe asthma. J Asthma Allergy. 2021;14:713–725. doi:10.2147/JAA.S305513.
   PubMed Web of Science ®Google Scholar
• Lommatzsch M, Korn S, Plate T, Grund T, Watz H. Early benefits in patient-reported outcomes (PROs) and physical activity (PA) in patients with severe eosinphilic asthma (SEA) treated with benralizumab: interim analysis of the imPROve asthma study. Paper presented at: European Respiratory Society International Congress 2022; September 4–6, 2022. Barcelona, Spain.
   Google Scholar